Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Non Operating Income (2022 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Non Operating Income for 4 consecutive years, with -$8.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 364.73% to -$8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Dec 2025, down 99.99% year-over-year, with the annual reading at $1000.0 for FY2025, 99.99% down from the prior year.
  • Non Operating Income hit -$8.0 million in Q4 2025 for ARS Pharmaceuticals, down from $2.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $3.8 million in Q1 2023 to a low of -$8.0 million in Q4 2025.
  • Historically, Non Operating Income has averaged $1.6 million across 4 years, with a median of $2.8 million in 2024.
  • Biggest five-year swings in Non Operating Income: surged 6521.28% in 2023 and later tumbled 364.73% in 2025.
  • Year by year, Non Operating Income stood at $1.2 million in 2022, then skyrocketed by 164.99% to $3.1 million in 2023, then decreased by 1.08% to $3.0 million in 2024, then crashed by 364.73% to -$8.0 million in 2025.
  • Business Quant data shows Non Operating Income for SPRY at -$8.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.7 million in Q2 2025.